This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teng, Y. Articles by Bates, P. J. Search for Related Content PubMed PubMed Citation Articles by Teng, Y. Articles by Bates, P. J.

AS1411 Alters the Localization of a Complex Containing Protein Arginine Methyltransferase 5 and Nucleolin

Departments of ¹ Medicine, ² Biochemistry and Molecular Biology, ³ Pharmacology and Toxicology, James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky

Requests for reprints: Paula J. Bates, University of Louisville, 580 South Preston Street, Delia Baxter Building 321, Louisville, KY 40202-1756. Phone: 502-852-2432; Fax: 502-852-2356; E-mail: paula.bates{at}louisville.edu.

AS1411 is a quadruplex-forming oligonucleotide aptamer that targets nucleolin. It is currently in clinical trials as a treatment for various cancers. We have proposed that AS1411 inhibits cancer cell proliferation by affecting the activities of certain nucleolin-containing complexes. Here, we report that protein arginine methyltransferase 5 (PRMT5), an enzyme that catalyzes the formation of symmetrical dimethylarginine (sDMA), is a nucleolin-associated protein whose localization and activity are altered by AS1411. Levels of PRMT5 were found to be decreased in the nucleus of AS1411-treated DU145 human prostate cancer cells, but increased in the cytoplasm. These changes were dependent on nucleolin and were not observed in cells pretreated with nucleolin-specific small interfering RNA. Treatment with AS1411 altered levels of PRMT5 activity (assessed by sDMA levels) in accord with changes in its localization. In addition, our data indicate that nucleolin itself is a substrate for PRMT5 and that distribution of sDMA-modified nucleolin is altered by AS1411. Because histone arginine methylation by PRMT5 causes transcriptional repression, we also examined expression of selected PRMT5 target genes in AS1411-treated cells. For some genes, including cyclin E2 and tumor suppressor ST7, a significant up-regulation was noted, which corresponded with decreased PRMT5 association with the gene promoter. We conclude that nucleolin is a novel binding partner and substrate for PRMT5, and that AS1411 causes relocalization of the nucleolin-PRMT5 complex from the nucleus to the cytoplasm. Consequently, the nuclear activity of PRMT5 is decreased, leading to derepression of some PRMT5 target genes, which may contribute to the biological effects of AS1411.

This article has been cited by other articles:

				H. Tanaka, Y. Hoshikawa, T. Oh-hara, S. Koike, M. Naito, T. Noda, H. Arai, T. Tsuruo, and N. Fujita PRMT5, a Novel TRAIL Receptor-Binding Protein, Inhibits TRAIL-Induced Apoptosis via Nuclear Factor-{kappa}B Activation Mol. Cancer Res., April 1, 2009; 7(4): 557 - 569. [Abstract] [Full Text] [PDF]

				D. Michalowski, R. Chitima-Matsiga, D. M. Held, and D. H. Burke Novel bimodular DNA aptamers with guanosine quadruplexes inhibit phylogenetically diverse HIV-1 reverse transcriptases Nucleic Acids Res., December 1, 2008; 36(22): 7124 - 7135. [Abstract] [Full Text] [PDF]